Company intelligence / Profile preview

ALPS Biotech Co., Ltd.

Nangang Dist. 115, Taipei City, Taiwanalps.com.tw ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

ALPS Biotech focuses on the discovery and development of new drugs from natural products using proprietary analytical platforms. Their pipeline includes preclinical candidates targeting cancer, infectious diseases, nervous system diseases, and radiation injuries. The company leverages proteomics and early cancer screening technologies to enhance treatment effectiveness and quality of life for end-stage cancer patients. No clinical trial results have been published as of January 2025.

Therapeutic areas: OtherOncologyNeurologyInfectious Diseases
Modalities: Herbal medicineSmall molecule drugMonoclonal antibody
Industry: Biotech

Partnerships

Collaborates with professional groups/doctors across specialties; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on ALPS Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALPS Biotech Co., Ltd..

Explore the full profile